Evotec invests €15m to further AI-driven drug discovery

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/monsitj)
(Image: Getty/monsitj)

Related tags: Drug discovery, Investment, Artificial intelligence

Evotec AG has acquired a minority stake in Exscientia – a company focused on artificial intelligence (AI)-driven drug discovery and design.

According to the company, the €15m ($17.63) investment will enable Exscientia to “drive higher value partner programs​” and expand discovery on its automated design platform.

As part of the transaction, Evotec’s Chief Operating Officer, Dr. Mario Polywka, will join Exscientia's Board of Directors.

The investment is the company’s largest single biggest equity placement to date, Dr. Werner Lanthaler, Evotec CEO explained in a press release.

The companies have worked together​ since 2016.

Working with Exscientia on a joint immuno-oncology project over the past year, we have experienced first-hand how its AI approaches, along with our medicinal chemistry platform, can positively and radically impact drug discovery​,” explained Lanthaler.

Exscientia, CEO, Prof. Andrew Hopkins added that the investment will allow Exscientia “to deliver more drug discovery projects in a rapid and capital efficient manner​.”

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Related suppliers

Follow us

Products

View more

Webinars